orantinib has been researched along with su 5402 in 2 studies
| Studies (orantinib) | Trials (orantinib) | Recent Studies (post-2010) (orantinib) | Studies (su 5402) | Trials (su 5402) | Recent Studies (post-2010) (su 5402) |
|---|---|---|---|---|---|
| 110 | 19 | 36 | 191 | 0 | 77 |
| Protein | Taxonomy | orantinib (IC50) | su 5402 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1867 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.2675 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 2.0262 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.1867 | |
| Fibroblast growth factor receptor 1 | Mus musculus (house mouse) | 10 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.1136 | |
| Vascular endothelial growth factor receptor 1 | Mus musculus (house mouse) | 0.4 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, C; McMahon, G; Rice, A; Schreck, R; Shawver, LK; Sun, L; Tang, C; Tang, F; Tran, N; Waltz, K | 1 |
| Al-awar, R; Fladd, C; Jiang, C; Nguyen, L; Prakesch, M; Rotin, D; Trzcinska-Daneluti, AM; Uehling, D | 1 |
2 other study(ies) available for orantinib and su 5402
| Article | Year |
|---|---|
Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.
Topics: Drug Design; Drug Evaluation, Preclinical; Endothelial Growth Factors; Enzyme Inhibitors; Fibroblast Growth Factors; Humans; Indoles; Lymphokines; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Platelet-Derived Growth Factor; Receptor Protein-Tyrosine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1999 |
Use of kinase inhibitors to correct ΔF508-CFTR function.
Topics: Animals; Benzazepines; Cell Line; Cricetinae; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dogs; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HEK293 Cells; Humans; Indoles; Ion Transport; Membrane Proteins; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Transport; Protein-Tyrosine Kinases; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; RNA Interference; RNA, Small Interfering; Sequence Deletion; Signal Transduction; Zearalenone | 2012 |